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Abstract: Cytotoxic drugs, which are commonly used for the pharmacotherapy of many forms of cancer, often
cause substantial toxicity to the patient without being able to induce long-lasting remissions. Ligands specific
to accessible tumor-associated targets, capable of selective localization at the neoplastic site, may facilitate the
preferential delivery of anti-cancer drugs, boosting activity and helping spare normal organs. In this article, we
present a critical analysis of the limitation of conventional anti-cancer drugs andwe contrast monoclonal antibod-
ies and small organic ligands, as vehicles for pharmacodelivery applications.
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The treatment of patients with various
forms of cancer (and especially those with
disseminated disease) often involves the
administration of cytotoxic drugs, which
are used to limit the uncontrolled tumor
growth and, ideally, induce a remission.
Historically, most anti-cancer drugs would
bind to nucleic acids or impact on their
production, acting as anti-metabolites.
Inhibitorsofchromatinfunctionordrugsaf-
fecting endocrine function are also used.
[1]
Over the last two decades, new classes
of small molecule anti-cancer drugs have
entered clinical practice, including kinase
inhibitors.
[2]
It is generally assumed that anti-cancer
drugs act directly on tumor cells, but the
interaction with endothelial cells
[3]
or with
certain leukocytes (e.g. regulatory T cells)
could also contribute to the therapeutic ef-
fect.
While chemotherapy can induce long-
lasting complete remissions in previously
incurable disseminated malignancies (e.g.
testicular cancer and certain hematological
cancer types), the majority of metastatic
forms of cancer cannot be cured by cyto-
toxic agents. One of the main limitations of
conventional cancer chemotherapy relates
to the inability of small organic drugs to
reach tumor cells. Nuclear medicine stud-
ies, performed in patients using radiola-
beled preparations of anti-cancer agents,
have shown that only a small portion of
the drug reaches the neoplastic masses in
vivo (Fig. 1).
[4]
These findings are consis-
tent with the results of many quantitative
biodistribution investigations, performed
in tumor-bearing rodents, which indicate a
limited ability of most conventional anti-
cancer drugs to preferentially localize at
the site of disease.
[5]
In an attempt to improve the pharma-
cokinetic properties of anti-cancer drugs,
antibodies, small ligands and polymers
have been proposed as pharmacodelivery
vehicles, with the aim to preferentially re-
lease cytotoxic payloads at the site of dis-
ease, sparing normal organs. In this article,
we will solely focus on ligand-based drug
delivery strategies (i.e. on antibody–drug
conjugates (ADCs) and small molecule–
drug conjugates (SMDCs); Fig. 2).
Antibody–Drug Conjugates
Three main facts have prompted re-
searchers to use antibodies as vehicles for
drug delivery: i) the exquisite specificity
by which they can recognize target anti-
gens; ii) the fact that monoclonal anti-
bodies can be raised against virtually all
proteins of interest; iii) previous experi-
ence with radiolabeled antibody products,
which aimed at concentrating therapeutic
radionuclides at the tumor site. Cytotoxic
drugs represent a convenient class of non-
radioactive anti-cancer payloads.
The main milestones in the develop-
ment of therapeutic ADCs have been re-
viewed elsewhere
[6,7]
and will not be re-
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Fig. 1. Positron Emission Tomography imaging of a mesothelioma patient, who received
11
C-labeled docetaxel. At no time point were the neoplastic lesions visible, while a substantial ac-
cumulation of the drug in other organs could be observed. Reproduced from ref. [4] with permis-
sion of the Springer International Publishing Group.
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ceived FDA approval for the treatment of
patients with HER2-positive metastatic
breast cancer who had previously received
trastuzumab and a taxane, separately or in
combination.
[5]
However, the product has
recently failed to demonstrate superior-
ity over trastuzumab in combination with
standard chemotherapy, in a Phase III
clinical trial.
In some mouse models of cancer, anti-
bodies only target perivascular tumor cells,
but fail to reach deeper structures within
the neoplastic mass, due to the so-called
‘antigen barrier’.
[12]
Limited information
is available, regarding the homogeneity of
tumor-targeting in humans, as these exper-
iments require access to cancer biopsies.
Not all ADC products are compatible with
a ‘bystander effect’, whereby the toxic
payload could migrate from the initial site
of tumor killing and attack neighboring
cancer cells.
The majority of ADC products that
have been investigated in the clinic exhib-
ited certain levels of bone marrow toxicity,
even though the cognate antigen was not
expressed in that compartment. It is likely
that premature drug release may contribute
to these side effects. In addition, complete
responses have been reported in patients
treated with Adcetris™, who did not ex-
hibit a detectable expression of the cognate
CD30 antigen.
[13]
It is not clear, at this mo-
ment in time, whether the observation of
ADC activity in antigen-negative patients
is due to technical problems in the execu-
tion of immunohistochemical experiments
or to an intrinsic property of the antibody–
drug conjugate, which circulates in blood
for several days and slowly releases its cy-
totoxic payload.
the treatment of certain forms of Hodgkin’s
Lymphoma and Anaplastic Large Cell
Lymphoma) and Kadcyla™ (for the sec-
ond-line treatment of HER2-positive met-
astatic breast cancer) (Fig. 3). Adcetris™
was approved on the basis of the high pro-
portion of objective responses, observed in
patients, who did not have a therapeutic al-
ternative.
[10]
These initial findings have lat-
er been confirmed in a double-blind Phase
III clinical trial, administering the product
as consolidation therapy after autologous
stem-cell transplantation in patients with
Hodgkin’s Lymphoma at risk of relapse or
progression.
[11]
Kadcyla™ is composed by the anti-
HER-2 humanized antibody trastuzumab,
coupled to the potent maytansinoid DM1
via a non-cleavable linker. It is believed
that the payload is released inside the tu-
mor cells, after ADC internalization and
subsequent proteolytic digestion of the
antibody moiety in an endo-lysosomal
compartment.
[5]
In 2013, Kadcyla™ re-
peated here. It is important to mention,
though, that after the first wave of ADC
products, based on low-potency payloads
(e.g. doxorubicin, methotrexate deriva-
tives), researchers have rapidly realized
that only ultra-potent drugs allow the gen-
eration of ADCs, which can be adminis-
tered at reasonably low dose, for which
production costs are still acceptable. An
alternative strategy, which is still being
pursued by a number of companies, makes
use of medium-potency anti-cancer drugs,
which are attached in numerous copies to
the antibody molecule, by means of multi-
valent (e.g. dendrimeric) linkers.
In general, ADCs are developed on the
basis of tumor-targeting antibodies, direct-
ed against an antigen on the surface of the
tumor cell, which rapidly internalizes, thus
acting as a ‘Trojan horse’ for the delivery
and subsequent release of a cytotoxic pay-
load inside the cell. The strict requirement
for ADC internalization has recently been
challenged. Evidence of potent activity
in preclinical models of cancer has been
reported for non-internalizing ADC prod-
ucts, directed against a number of targets,
including collagen IV, fibrin, splice iso-
forms of fibronectin and of tenascin-C.
[8]
The therapeutic activity and selectivity
of ADC products in preclinical models of
cancer can be sensational. For example,
brentuximab vedotin (a product marketed
under the trade name of Adcetris™) cured
tumor-bearingmice at doses as lowas1mg/
Kg, corresponding to 1/30
th
of the maximal
tolerated dose.
[9]
Unfortunately, the thera-
peutic window ofADC products appears to
be less wide in patients, for reasons which
are still not completely understood. It is
possible that the tumor:organ ratios ob-
served with ADC products in tumor-bear-
ing mice are substantially better, compared
to the values observed in patients with can-
cer. Quantitative biodistribution studies in
rodent models and dosimetric findings in
Nuclear Medicine trials suggest that this
may indeed be the case.
TwoADCproductshaverecentlygained
marketing authorization: Adcetris™ (for
mAb Linker Drug Ligand Linker Drug
Antibody-Drug Conjugate (ADC) Small Molecule-Drug Conjugate (SMDC)
Fig. 2. Schematic representation of the basic elements in antibody–drug conjugates and small
molecule–drug conjugates.
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Fig. 3. Schematic representation of the structure of Adcetris™ and Kadcyla™. In the first case,
monomethyl auristatin E (MMAE), equipped with a cleavable linker, is coupled to the cysteine
residues of an anti-CD30 chimeric antibody. In the second case, the potent maytansinoid DM1
is coupled to primary amino groups of the humanized anti-HER2 antibody trastuzumab using a
stable linker.
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The role that DNA-encoded chemical
library technology can play for the devel-
opment of SMDC products is illustrated
in the following example. Mice bearing
subcutaneously-grafted renal cell carcino-
ma xenografts were injected with a near-
infrared fluorescent dye or with dye de-
rivatives, coupled to acetazolamide or to a
high affinity acetazolamide derivative (Kd
= 200 pM), isolated from a DNA-encoded
chemical library
[31]
(Fig. 4). Fluorescence
imaging procedures revealed that the un-
conjugated dye was not able to localize to
the tumor and was rapidly excreted, in full
analogy to the behavior of standard che-
motherapeutic drugs, illustrated in Fig. 1.
By contrast, the dye conjugate with acet-
azolamide revealed a rapid and selective
tumor targeting, which was visible already
1 hour after intravenous administration.
The intermediate affinity of the conjugate
towards CAIX (Kd = 8 nM) did not allow
a long residence time on the neoplastic le-
sion. By contrast, the higher affinity CAIX
targeting agent, exhibited a rapid, long-
lasting and selective accumulation in the
tumor mass (Fig. 4). Similar results were
obtained in quantitative biodistribution
studies, using the same ligands equipped
with a technetium-99m chelator and radio-
active counting techniques.
[23]
Future Perspectives
ADCs and SMDCs are prodrugs with
the potential to substantially improve the
therapeutic index of the corresponding
cognate drug. Numerous products (espe-
cially ADCs) are currently being investi-
gated in clinical trials, even though many
companies are reducing their research and
development activities in the field, after
substantial initial investments. One of the
main unresolved challenges, which com-
does not internalize upon binding with
small heteroaromatic sulfonamides and
SMDC products, featuring acetazolamide
as tumor-homing moiety, exhibit a potent
anti-cancer activity in preclinical models.
Both DM1 (the payload of Kadcyla™) and
MMAE (the payload of Adcetris™) have
been coupled to acetazolamide using link-
ers that can be cleaved in the extracellular
space. The corresponding products exhib-
ited a promising anti-cancer activity,
[19,22]
which was superior to that of sunitinib
and sorafenib (two standard drugs for the
treatment of metastatic kidney cancer) in
tumor-bearing mice.As for SMDCs target-
ing the folate receptor or PSMA, the tumor
targeting performance of CAIX ligands
can be monitored using
99m
Tc-labeled com-
panion diagnostics.
[22,23]
Other targets for the development of
SMDC products include somatostatin re-
ceptors, the aminopeptidase CD13 and
certain integrins. Unlike antibodies, which
can be raised against virtually any anti-
gen, small molecule protein ligands can
be difficult to generate, depending on the
nature of the cognate target. Nowadays,
fully human monoclonal antibodies can be
rapidly isolated from large combinatorial
phage display libraries, containing billions
of different specificities.
[24]
The advent of
DNA-encoded combinatorial chemical li-
braries allows the creation and screening
of compound collections of unprecedented
size,
[25–30]
thus facilitating ligand discov-
ery. These libraries are composed of small
organicmolecules, individually attached to
distinctive DNA fragments serving as am-
plifiable identification barcodes. Members
of DNA-encoded combinatorial libraries
can be screened simultaneously by selec-
tion with the target protein of interest, im-
mobilized on a solid support. Preferential
binders are identified by high-throughput
DNA sequencing techniques.
Small Molecule–Drug Conjugates
Antibodies in IgG format exhibit a long
circulatory half-life (mediated by interac-
tion with the neonatal Fc receptor FcRn)
and extravasate slowly. As a result, accept-
ably high tumor:organ ratios are observed
in vivo only several days after intravenous
administration.
[14]
The suboptimal biodis-
tribution properties of immunoglobulins
have prompted researchers to use small
organic ligands as alternative vehicles for
drug delivery applications. Unlike antibod-
ies, small organic molecules can get out of
blood vessels in a matter of seconds.
[15]
In the absence of a suitable binding event
(e.g. recognition of a membrane antigen
or of an extracellular matrix component),
small molecules rapidly diffuse back into
blood and can be excreted. However, small
ligands with a sufficiently high binding af-
finity to accessible tumor-associated anti-
gens can exhibit excellent tumor:blood and
tumor:organ ratios, combining a rapid ex-
travasation, a rapid elimination and a long
residence time at the site of disease.
[5,16]
Suitable ligands for drug delivery applica-
tions include folate analogues,
[16,17]
pros-
tate-specific membrane antigen (PSMA)
ligands
[18]
and binders to carbonic anhy-
drase IX (CAIX).
[19]
A folate–vinblastin conjugate, devel-
oped by Endocyte, exhibited encouraging
clinical results for the treatment of ad-
vanced ovarian cancer, especially in pa-
tients with high uptake of a radiolabeled
folate derivative used as companion diag-
nostic.
[20]
These data led to a conditional
approval in Europe, but product develop-
ment activities were later discontinued on
the basis of disappointing Phase III trial
results.
Encouraging preclinical results with
PSMA ligand derivatives
[19]
have motivat-
ed Endocyte to develop an SMDC prod-
uct for the treatment of advanced prostate.
The drug conjugate EC1169 makes use of
a very potent tubulysin payload and is cur-
rently being investigated in a Phase I clini-
cal trial, together with a companion diag-
nostic product. Therapeutic radionuclides
have been considered as an alternative av-
enue for arming PSMA ligands. A recent
clinical report on 148 patients with meta-
static castration-resistant prostate cancer,
treated with the
177
Lu-labeled-PSMA-617
radiopharmaceutical, evidenced favorable
safety and excellent efficacy, with >40% of
subjects enjoying an objective biochemical
and radiological response.
[21]
Carbonic anhydrase IX is a homodi-
meric membrane protein, which shows
restricted expression in normal tissues,
mainly limited to certain structures in
the gastro-intestinal tract, but intense ex-
pression in renal cell carcinoma and in
a number of other malignancies. CAIX
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Fig. 4. Near-infrared fluorescence imaging of tumor-bearing mice, imaged at various time points
following intravenous injection of a dye, or of the same dye coupled to two different CAIX ligands,
differing in binding affinity to the target. Adapted from ref. [31].
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plicates the clinical and industrial develop-
ment of ligand-based targeted cytotoxics,
relates to the difficulty in translating prom-
ising preclinical results (i.e. cancer cures in
tumor-bearing mice) into a corresponding
clinical activity. A reliable quantification
of the concentration of cytotoxic agent de-
livered to neoplastic lesions in mouse and
man will be of fundamental importance,
in order to rationally advance ADC and
SMDC research.
Nuclear medicine imaging studies will
be extremely useful, in order to quantify
product uptake. In particular, it will be im-
portant to learn whether lesions that benefit
most from pharmacological treatment are
also the ones with the highest product up-
take. At present, these studies are hindered
both by the complexity of coordinating
oncology and nuclear medicine investiga-
tions in the same patient and by regulatory
aspects (e.g. GMP preparations both for
the unlabeled and labeled products).
Until now, clinical-stage ADC and
SMDC products have rarely demon-
strated an ability to induce cancer cures
in patients, when used as monotherapy.
The opportunity to combine targeted cy-
totoxics with certain immunostimulatory
drugs is becoming increasingly attractive,
also in view of the growing role played by
immune-oncology drugs for the treatment
of patients with metastatic disease. The
antibody-based delivery of interleukin-2
(IL2, a potent activator of T cells and NK
cells) has been shown to potentiate che-
motherapy in preclinical models of cancer,
especially when administered after the cy-
totoxic agent.
[32]
Similarly, the anti-cancer
activity of ADCs
[33,34]
and SMDCs
[35]
has
been shown to be potentiated by tumor-
targeting antibody-IL2 fusion proteins.
It is likely that the tumor becomes more
immunogenic, after the insult caused by
the action of cytotoxics. Possible mecha-
nisms may involve the up-regulation of
stress surface proteins on tumor cells (e.g.
MIC-A) and the subsequent recognition by
NK cells, or the increased presentation of
tumor-associated peptides on MHC class I
molecules.
Looking into the future, we anticipate
that ADCs and SMDCs may play an in-
creasingly important role not only in on-
cology, but also for the delivery of other
classes of drugs (e.g. antibiotics, anti-in-
flammatory drugs).
[36]
In our opinion, the
therapeutic potential of ligands coupled to
small organic drugs will be best exploited
in combination with innovative immuno-
modulatory modalities, such as immuno-
logical check-point inhibitors or antibody–
